Merck Discontinues Substance P Depression Compound After Failed Trial
Executive Summary
Merck is abandoning its efforts to develop the substance P antagonist aprepitant (MK-0869) for treatment of depression
You may also be interested in...
Merck After Vioxx: No Merger, But No Big Near-Term Launches
Following Merck's decision to withdraw Vioxx from the market, an FDA approval of the follow-on COX-2 inhibitor Arcoxia is likely to be delayed
Merck After Vioxx: No Merger, But No Big Near-Term Launches
Following Merck's decision to withdraw Vioxx from the market, an FDA approval of the follow-on COX-2 inhibitor Arcoxia is likely to be delayed
Merck Gets Second Chance On Dual PPAR: Will Develop Bristol’s Muraglitazar
Merck's co-development agreement for Bristol Myers-Squibb's Phase III muraglitazar gives the company a second chance to market a dual PPAR agonist